Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 2/3 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 6Oxaliplatin 5Cyclophosphamide 4Azacitidine 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × regorafenib × Clear all
NCT07379047 2026-04-24

GISTAR-1

Ningbo Newbay Technology Development Co., Ltd

Phase 2/3 Not yet recruiting
255 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3 Not yet recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡